Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × OTHER × pomalidomide × Clear all

Phase

Phase 2 47 Phase 1/2 17 Phase 1 12 Phase NA 7 Phase 3 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Cisplatin 44 Fluorouracil 39 Cyclophosphamide 37 Oxaliplatin 34 Capecitabine 31 Docetaxel 29 Drug Therapy 28 Gemcitabine 26 Radiotherapy 24 Paclitaxel 23 Leucovorin 20 Dexamethasone 19 Carboplatin 18 Doxorubicin 16 apatinib 15 Etoposide 15 Methotrexate 14 Cytarabine 14 Magnetic Resonance Spectroscopy 13 Epirubicin 12 Busulfan 12 Radiation 11 Bevacizumab 11 Surgical Procedures, Operative 10 Decitabine 10 venetoclax 9 camrelizumab 9 Saline Solution 9 Radiosurgery 9 Neoadjuvant Therapy 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06879379 2025-03-17

KPD Consolidation After ASCT in NDMM Patients

Peking University People's Hospital

Phase 2/3 Recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡